Tri Locum Partners LP: TEVA PHARMACEUTICAL INDS LTD (TEVA): Quarterly 13F Position History
As of Q1 2026, Tri Locum Partners LP reported 1,021,008 shares of TEVA PHARMACEUTICAL INDS LTD (TEVA), worth $30.8M and representing 4.3% of its 13F equity book. Quarter-over-quarter share count change: 414,857 (-28.9%) . The position first appeared in Q3 2022 and has been disclosed across 15 13F-HR filings in Pactolio's tracked window.
- 1,021,008Shares Held (Latest Filing)
- $30.8MReported Market Value (Latest Filing)
- 4.3%Portfolio Weight (% of 13F Equity Book)
- 414,857Quarter-over-Quarter Share Change
- -$14.1MQuarter-over-Quarter Value Change
- 2,755,737Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 15 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 1,021,008 | 414,857 | -28.9% | $30.8M | 4.3% | $30.1 |
| Q4 2025 | 1,435,865 | +1,435,865 | — | $44.8M | 5.8% | $31.2 |
| Q3 2025 | 0 | 2,046,846 | -100.0% | $0 | 0.0% | — |
| Q2 2025 | 2,046,846 | +985,838 | +92.9% | $34.3M | 10.4% | $16.8 |
| Q1 2025 | 1,061,008 | 1,362,108 | -56.2% | $16.3M | 8.4% | $15.4 |
| Q4 2024 | 2,423,116 | 332,621 | -12.1% | $53.4M | 11.1% | $22.0 |
| Q3 2024 | 2,755,737 | +205,430 | +8.1% | $49.7M | 11.9% | $18.0 |
| Q2 2024 | 2,550,307 | +334,119 | +15.1% | $41.4M | 10.5% | $16.3 |
| Q1 2024 | 2,216,188 | +421,853 | +23.5% | $31.3M | 10.8% | $14.1 |
| Q4 2023 | 1,794,335 | 838,558 | -31.8% | $18.7M | 9.2% | $10.4 |
| Q3 2023 | 2,632,893 | +1,527,123 | +138.1% | $26.9M | 8.6% | $10.2 |
| Q2 2023 | 1,105,770 | +93,397 | +9.2% | $8.3M | 3.1% | $7.5 |
| Q1 2023 | 1,012,373 | +1,012,373 | — | $9.0M | 2.7% | $8.8 |
| Q4 2022 | 0 | 683,613 | -100.0% | $0 | 0.0% | — |
| Q3 2022 | 683,613 | — | — | $5.5M | 1.6% | $8.1 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Tri Locum Partners LP first disclose a TEVA position in 13F-HR filings?
Tri Locum Partners LP first reported TEVA PHARMACEUTICAL INDS LTD (TEVA) on its 13F-HR filing for the period ending 2022-09-30 (Q3 2022). The position has appeared on 15 reported quarters within Pactolio's tracked window.
What was Tri Locum Partners LP's most recent quarter-over-quarter share-count change in TEVA?
Between Q4 2025 and Q1 2026, Tri Locum Partners LP reduced its TEVA position by 414,857 shares (-28.9%), leaving 1,021,008 shares at a market value of $30.8M.
Does the implied price-per-share represent Tri Locum Partners LP's cost basis in TEVA?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.